Considering the substantial residual risk for recurrent events in LDL‐c‐lowering therapy, which remains the cornerstone for prevention and treatment of ASCVD currently,[5] our identification of PSRC1 targeting medium HDL with therapeutic potential for CAD might bring new opportunity to tackle such residual risk issue and optimize long‐term lipid‐modifying therapies a step further. The gene discussed is PSRC1; the disease is atherosclerosis.